Regulator of G‐Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l‐Dopa‐induced dyskinesia. (12th January 2022)

• Record Type: Journal Article
• Authors: Pisanò, Clarissa A.; Mercatelli, Daniela; Mazzocchi, Martina; Brugnoli, Alberto; Morella, Ilaria; Fasano, Stefania; Zaveri, Nurulain T.; Brambilla, Riccardo; O'Keeffe, Gerard W.; Neubig, Richard R.; Morari, Michele
• Other Names: Traynor John guestEditor.; Moron‐Concepcion Jose guestEditor.
• Is Part Of: British journal of pharmacology. Volume 180:Number 7(2023)
• Page Start: 927
• Page End: 942
• Publication Date: 2022-01-12
• Subjects: AT‐403 -- CCG‐203920 -- dyskinesia -- l‐Dopa -- nociceptin/orphanin FQ -- RGS4; Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.15730
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Background and Purpose: Regulator of G‐protein signalling 4 (RGS4) is a signal transduction protein that accelerates intrinsic GTPase activity of Gαi/o and Gαq subunits, suppressing GPCR signalling. Here, we investigate whether RGS4 modulates nociceptin/orphanin FQ (N/OFQ) opioid (NOP) receptor signalling and if this modulation has relevance for l ‐Dopa‐induced dyskinesia. Experimental Approach: HEK293T cells transfected with NOP, NOP/RGS4 or NOP/RGS19 were challenged with N/OFQ and the small‐molecule NOP agonist AT‐403, using D1‐stimulated cAMP levels as a readout. Primary rat striatal neurons and adult mouse striatal slices were challenged with either N/OFQ or AT‐403 in the presence of the experimental RGS4 chemical probe, CCG‐203920, and D1‐stimulated cAMP or phosphorylated extracellular signal regulated kinase 1/2 (pERK) responses were monitored. In vivo, CCG‐203920 was co‐administered with AT‐403 and l ‐Dopa to 6‐hydroxydopamine hemilesioned rats, and dyskinetic movements, striatal biochemical correlates of dyskinesia (pERK and pGluR1 levels) and striatal RGS4 levels were measured. Key Results: RGS4 expression reduced NOFQ and AT‐403 potency and efficacy in HEK293T cells. CCG‐203920 increased N/OFQ potency in primary rat striatal neurons and potentiated AT‐403 response in mouse striatal slices. CCG‐203920 enhanced AT‐403‐mediated inhibition of dyskinesia and its biochemical correlates, without compromising its motor‐improving effects. Unilateral dopamine depletion caused bilateral reduction of RGS4 levels, which was reversed by l ‐Dopa. l ‐Dopa acutely up‐regulated RGS4 in the lesioned striatum. Conclusions and Implications: RGS4 physiologically inhibits NOP receptor signalling. CCG‐203920 enhanced NOP responses and improved the antidyskinetic potential of NOP receptor agonists, mitigating the effects of striatal RGS4 up‐regulation occurring during dyskinesia expression. LINKED ARTICLES: This article is part of a themed issue on Advances in Opioid Pharmacology at the Time of the Opioid Epidemic. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.7/issuetoc